Publication at First Faculty of Medicine |
2021
Abstract
Patients with generalized neuroendocrine tumors (NET) in the liver may suffer from severe carcinoid syndrome as the liver progresses. In some cases, established systemic therapy (especially somatostatin analogues) is not sufficient to manage clinical manifestations.
In such a situation, we use other available methods that can complement systemic therapy and help manage the side effects of the disease. One option is to use selective hepatic transarterial embolization (TAE) or transarterial chemoembolization (TACE).
The purpose of these methods is to prevent blood flow to tumor foci, which leads to their ischemia and eventually necrosis.